Dimericon Therapeutics is a seed-stage biotech company developing pre-clinical programs for hard-to-drug intracellular targets using a novel peptidic modality. The lead program is aimed at reactivation of extrinsic apoptosis in p53 mutated cancers with an initial focus on AML, MM and lung cancer and will enter the clinic in early 2027. Backed by a $14M seed round led by AbbVie Ventures and BiomedVC, with participation from the Leukemia & Lymphoma Society, Dimericon operates R&D hubs in Zurich and New York City.